<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Osteoporosis: diagnosis, treatment, and fracture prevention.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Medical Services Commission. Osteoporosis: diagnosis, treatment and fracture prevention. Vancouver (BC): British Columbia Medical Services Commission; 2011 May 1. 15 p.  [41 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Bone mineral density studies  (88.98); Fracture, cause unspecified  (E887); Osteoporosis, unspecified  (733.00)"/><FieldValue Value="MSH: Absorptiometry, Photon ; Accidental Falls ; Alendronate ; Antibodies, Monoclonal ; Bone Density ; Bone Density Conservation Agents ; Calcitonin ; Dietary Proteins ; Diphosphonates ; Estrogens ; Etidronic Acid ; Exercise ; Fractures, Bone ; Hormone Replacement Therapy ; Imidazoles ; Life Style ; Medical History Taking ; Osteoporosis ; Osteoporotic Fractures ; Progesterone ; Raloxifene ; Risk Assessment ; Selective Estrogen Receptor Modulators ; Smoking Cessation ; Teriparatide ; Vitamin D "/><FieldValue Value="MTH: Accidental Falls ; Bone Density ; Bone Mineral Density Test ; Calcitonin ; Cessation of smoking ; denosumab ; Diphosphonates ; Estrogens ; Etidronate ; Exercise ; Fall prevention ; Fracture ; Hormone replacement therapy ; Imidazoles ; Life Style ; Monoclonal Antibodies ; Osteoporosis ; Progesterone ; Risedronate ; Risk Assessment ; Selective Estrogen Receptor Modulators ; Teriparatide ; Vitamin D ; Vitamin D measurement ; zoledronic acid "/><FieldValue Value="PDQ: calcitonin ; denosumab ; etidronate ; osteoporosis ; progesterone ; raloxifene ; risedronate "/><FieldValue Value="SNOMEDCT_US: Accidental fall  (217082002); Alendronate  (96290008); Calcitonin  (63730009); Denosumab  (446321003); Denosumab  (446457007); Diphosphonate  (372907000); Diphosphonate  (96281001); Education about alcohol consumption  (281078001); Estrogen  (41598000); Estrogen  (61946003); Etidronate  (372908005); Etidronic acid  (420702005); Etidronic acid  (96284009); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Fall prevention  (386296001); Fracture  (125605004); Fracture  (72704001); Hormone replacement therapy  (266717002); Life style  (134436002); Life style  (60134006); Monoclonal antibody  (49616005); Osteoporosis  (64859006); Osteoporosis - falls prevention  (391027005); Osteoporosis risk assessment done  (391014006); Osteoporotic fracture  (46675001); Osteoporotic fracture probability score using World Health Organization fracture risk assessment tool  (446965002); Progesterone  (16683002); Progesterone  (50318003); Raloxifene  (109029006); Raloxifene  (419530003); Risedronate  (387582001); Risk assessment  (225338004); Selective estrogen receptor modulator  (109030001); Selective estrogen receptor modulator  (415515000); Teriparatide  (398823001); Teriparatide  (425438001); Vitamin D  (11563006); Vitamin D  (30178006); Vitamin D measurement  (83729008); Zoledronic acid  (134600006); Zoledronic acid  (395926009)"/><FieldValue Value="SPN: DENSITOMETER, BONE "/><FieldValue Value="UMD: Densitometers, Bone  (17-152); Densitometers, Bone, X-Ray, Dual-Energy Absorptiometry  (17-747)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Osteoporosis and related fractures&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To summarize current recommendations for risk estimation, diagnosis, prevention, and treatment of osteoporosis and related fractures in a general adult population (age 19+ years)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;General adult population (age 19+ years)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Assessment/Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Risk assessment for osteoporosis or fracture using the FRAX&amp;reg; calculator or Canadian Association of Radiologists and Osteoporosis Canada (CAROC) risk table &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk stratification &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dual-energy X-ray absorptiometry (DXA) bone mineral density scan (as indicated) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medical history &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Laboratory testing of bone turnover markers and vitamin D (considered but not recommended for diagnosis or risk assessment) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical re-assessment and monitoring as indicated &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Lifestyle advice on exercise; calcium, vitamin D, and protein intake; smoking cessation; and alcohol intake &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Falls prevention strategies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacological therapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Bisphosphonates (alendronate, etidronate, risedronate, zoledronic acid) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Selective estrogen receptor modulators (SERMs) (raloxifene) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Receptor activator of nuclear factor-kB (RANK) ligand inhibitor (denosumab) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Synthetic parathyroid hormone (teriparatide) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Calcitonin &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Hormone replacement therapy (HRT) (estrogen with or without progesterone) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Risk of developing osteoporosis (OP) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk of fracture within 10 years &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk of falling &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medication side effects &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The systematic literature follows the Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009) document methodology. Evidence was obtained through a systematic review of peer-reviewed literature (up to 2010) using the databases MEDLINE, PubMed, EBSCO, Ovid, and the Cochrane Collaboration's Database for Systematic Reviews. Clinical practice guidelines from other jurisdictions for osteoporosis were also reviewed (up to 2009).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Not stated" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline developers reviewed published cost analyses.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline was developed by the Guidelines and Protocols Advisory Committee, approved by the British Columbia Medical Association, and adopted by the Medical Services Commission.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Step 1: Assessment of Risks of Osteoporosis or Fracture&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There are two aspects of risk that can be explored by identifying known risk factors:&lt;/p&gt;&#xD;&#xA;&lt;ul&gt;&#xD;&#xA;    &lt;li&gt;Risk of developing osteoporosis (OP) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk of fracture within 10 years &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Risk of Developing Osteoporosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Risk of Developing Osteoporosis&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Family History&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Parental history of hip fracture&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Medical History&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Advanced age &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Frailty* &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Hyperthyroidism (including iatrogenic) or hyperparathyroidism &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Celiac and other malabsorption syndromes &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Bone mass index (BMI) &amp;lt;20 kg/m&lt;sup&gt;2&lt;/sup&gt; or weight loss &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Medication history, particularly chronic glucocorticoid use** (see Appendix A in the original guideline document) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Rheumatoid arthritis &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Chronic liver or kidney disease &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;For Men&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Androgen deficiency (primary or secondary)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;For Women&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Estrogen deficiency (primary or secondary) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Early menopause (&amp;lt;45 years), including surgical &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cessation of menstruation for 6-12 consecutive months (excluding pregnancy, menopause or hysterectomy) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Lifestyle&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Smoking (current or former) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Daily alcohol consumption &amp;gt;3 units (1 unit = 5 oz wine, 1.5 oz spirits, 12 oz beer) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Caffeine intake &amp;gt;4 cups/day &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Inadequate calcium and vitamin D intake &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Lack of sunlight exposure (may cause vitamin D deficiency) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Prolonged immobility and lack of weight-bearing exercise &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;* See &lt;a href=&quot;http://www.BCGuidelines.ca&quot; title=&quot;BC Ministry of Health Web site&quot;&gt;www.BCGuidelines.ca&lt;/a&gt; &amp;ndash; &lt;em&gt;Frailty in Older Adults &amp;ndash; Early Identification and Management&lt;/em&gt; for definition&lt;br /&gt;&#xD;&#xA;** i.e., &amp;ge;3 months (consecutive) therapy at a dose of prednisone &amp;ge;7.5 mg per day or equivalent&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Calculate the 10-year Fragility Fracture Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The fracture risk of a patient can be estimated as Low (&amp;lt;10% in next 10 years), Moderate (10 - 20% in next 10 years), or High (&amp;gt;20% in next 10 years) using known risk factors and a clinical assessment tool. There are two tools available to calculate 10-year fracture risk. One is the FRAX&amp;reg; (see Appendix C - Using the FRAX&amp;reg; Calculator to Assess Absolute Fracture Risk in the original guideline document), developed by the World Health Organization (WHO), and the other is produced by the Canadian Association of Radiologists and Osteoporosis Canada (CAROC).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;FRAX&amp;reg;* employs a web-based (&lt;a href=&quot;http://www.shef.ac.uk/FRAX&quot; title=&quot;FRAX Web site&quot;&gt;www.shef.ac.uk/FRAX&lt;/a&gt;) calculator that includes a number of risk factors, including bone mineral density (BMD) which is optional. The CAROC paper-based risk table takes into account age, sex, fracture history, and glucocorticoid use to determine a ten-year absolute risk of all osteoporotic fractures, but BMD is required to calculate risk.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;* Although the FRAX&amp;reg; tool has been developed for prognosis and is not prescriptive, this guideline suggests the use of a tool to identify all risk groups for whom treatment will depend on individual clinical parameters and specific therapeutic indications listed in Steps 3 and 4 (e.g., age, previous vertebral fracture, T score, where appropriate).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Falls and the Risk of Fracture (also see &quot;Falls Prevention Strategies,&quot; below)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Over and above the risk of OP, other clinical factors predict those at increased risk of fracture, including:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Previous fragility fracture&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Fractures sustained in falls from standing height or less, in which bone damage is disproportional to the degree of trauma. Includes vertebral compression fractures not attributable to previous major trauma, which may be suggested by height loss. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where other disease has been ruled out, patients with low trauma fragility fractures may have OP and are at &lt;strong&gt;high&lt;/strong&gt; risk of other fragility fractures within 10 years. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fractures of the hip, vertebra, humerus, and wrist are most closely associated with OP and increased future fracture risk whereas those of the skull, fingers, toes, and patella fractures are not. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A fall in the last year&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;High risk of falling as determined by&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Physical frailty or significant weight loss (loss of muscle mass). Refer to &lt;a href=&quot;http://www.BCGuidelines.ca&quot; title=&quot;BC Ministry of Health Web site&quot;&gt;www.BCGuidelines.ca&lt;/a&gt; - &lt;em&gt;Frailty in Older Adults &amp;ndash; Early Identification and Management&lt;/em&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A global assessment of functional mobility like the timed &quot;Up and Go&quot; test &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Poor strength &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Balance problems &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gait problems &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dizziness &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Poor vision &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychotropic medications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cardiac insufficiency &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Urinary frequency and toileting issues &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Other validated tests &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Step 2: Risk Stratification&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Fracture risk estimation, using known risk factors and a clinical assessment tool, can be used to categorize patients as Low (&amp;lt;10% in next 10 years), Moderate (10 &amp;ndash; 20% in next 10 years) or High (&amp;gt;20% in 10 years) fracture risk.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Risk Stratification Using Dual-Energy X-Ray Absorptiometry BMD&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;BMD is not indicated unless patients (men and women) are age &amp;gt;65 years, at moderate risk of fracture (10 - 20% 10-year risk), and results are likely to alter patient care.&lt;/strong&gt; There has been a shift away from BMD and towards emphasizing multivariate fracture risk using a risk calculation model (FRAX&amp;reg; or CAROC). BMD is not recommended to be used alone as it explains only a portion of fracture risk. If a clinical risk assessment tool suggests moderate fracture risk category, consider BMD testing to further stratify risk and guide treatment; if high risk, consider treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;BMD is NOT indicated for:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Investigation of chronic back pain &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Investigation of exaggerated dorsal kyphosis (fractures are best excluded by radiography) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screening women aged &amp;lt;65 years, unless significant clinical risk factors have been identified &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Part of a routine evaluation around the time of menopause &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Confirmation of OP when a fragility fracture occurs &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;T-score classification (number of standard deviations above or below the mean peak BMD):&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Normal&lt;/em&gt;: T is -1 and above &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Osteopenia&lt;/em&gt;: T is -1.1 to -2.4 &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Osteoporosis&lt;/em&gt;: T -2.5 and below &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Established or severe OP&lt;/em&gt;: T is -2.5 or below and one or more prevalent low-trauma fractures &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Dual-energy X-ray absorptiometry&amp;nbsp;(DXA) is a quantitative test and it requires careful quality assurance. Structural abnormalities, positioning, artifacts (e.g., body weight), and analysis can significantly affect results.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Laboratory Testing (Bone Turnover Markers and Vitamin D)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Indications&lt;/em&gt;: Blood tests are &lt;span style=&quot;text-decoration: underline;&quot;&gt;not&lt;/span&gt; indicated to make an OP diagnosis or determine risk. Blood tests are only useful to establish or to rule out secondary causes of OP. Refer to &lt;em&gt;Appendix B - Testing for Suspected Secondary Causes of OP in Selected Patients&lt;/em&gt; in the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Bone turnover markers&lt;/em&gt;: At present no single or combined assay is recommended except in specific circumstances. Assays have a proven use in research studies involving large samples but they are complex and variation is too great to be useful at the individual level.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Vitamin D&lt;/em&gt;: Routine testing is not required to diagnose OP or before/after starting vitamin D supplementation. Refer to &lt;a href=&quot;http://www.BCGuidelines.ca&quot; title=&quot;BC Ministry of Health Web site&quot;&gt;www.BCGuidelines.ca&lt;/a&gt; - &lt;em&gt;Vitamin D Testing Protocol&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Step 3: Lifestyle Advice (Regardless of Risk Level)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Nutrition&lt;/em&gt;: Help reduce fracture risk via adequate daily calcium and vitamin D. Note: doses recommended below for calcium and vitamin D represent total intake from diet and supplements.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Calcium: Recommend 1000-1200 mg elemental calcium per day including supplements, if necessary. See OP &lt;em&gt;Patient Guide&lt;/em&gt; (see the &quot;Patient Resources&quot; field). Advise patients not to exceed recommended amounts, as evidence does not support higher doses of calcium supplementation. In addition, a 2010 meta-analysis reported an increase in myocardial infarction in men and women given calcium supplementation (i.e., &amp;ge;500 mg elemental calcium per day) versus placebo. Note: this meta-analysis studied calcium supplementation alone and not in combination with vitamin D and the increased risk was associated with dietary intakes of greater than 800 mg (approximately) elemental calcium per day. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vitamin D: Recommend 800-1000 IU per day of vitamin D&lt;sub&gt;3&lt;/sub&gt;, including supplements if necessary, to adults over the age of 50. Higher doses (i.e., 2000 IU per day) may be needed in some cases and are considered safe. See Patient Guide (see the &quot;Patient Resources&quot; field) and &lt;a href=&quot;http://www.BCGuidelines.ca&quot; title=&quot;BC Ministry of Health Web site&quot;&gt;www.BCGuidelines.ca&lt;/a&gt; - &lt;em&gt;Vitamin D Testing Protocol&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Protein: Recommend an adequate intake of dietary protein (1g/kg/day). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Exercise&lt;/em&gt;: Regular weight-bearing and muscle-strengthening reduce the risk of falls and fractures by improving agility, strength, posture, and balance, as well as general health benefit.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Smoking&lt;/em&gt;: Tobacco products are detrimental to the skeleton as well as to overall health.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Alcohol&lt;/em&gt;: Intake of 3 or more units (5 oz wine, 1.5 oz spirits, 12 oz beer) per day is detrimental to bone health and increases the risk of falling.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Step 4: Therapy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Falls Prevention Strategies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Falls prevention is the first line of treatment (versus OP medications) for those at high risk for falling.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table: Items to Identify Falls Risk and Reduce Falls&lt;/strong&gt; (review with patient at least annually)&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Items to Identify Falls Risk and Reduce Falls&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Ask about falls in the past year &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Assess the time taken to stand from sitting &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Assess muscle strength, balance, and gait by watching the patient walk and move &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Check and correct postural hypotension and cardiac arrhythmias &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Evaluate any neurological problems &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Review prescription medications that may affect balance &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Provide a checklist for improving safety at home, i.e., The Safe Living Guide-A Guide to Home Safety for Seniors, &lt;a href=&quot;http://www.phac-aspc.gc.ca/&quot; title=&quot;Public Health Agency of Canada Web site&quot;&gt;www.phac-aspc.gc.ca&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;Consider referral to geriatric medicine, a falls prevention program, homecare, occupational therapy, or physical therapy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Pharmacological Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See also &lt;em&gt;Appendix D - Pharmacological Therapy for Osteoporosis&lt;/em&gt; in the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Medications may be recommended, depending on fracture risk assessment. Manage based on degree of risk:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Low risk&lt;/em&gt;: Generally require lifestyle advice and daily intake of calcium and vitamin D. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Moderate risk&lt;/em&gt;: Medication is usually not necessary but can be considered in addition to lifestyle advice and adequate daily intake of calcium and vitamin D. When considering medications, take into account patient preference and additional clinical risk factors (see below). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table: Additional Clinical Risk Factors&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Additional Clinical Risk Factors&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Vertebral fractures (&amp;gt;25% height loss with end-plate disruption) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Lumbar spine BMD T-score that is significantly worse than hip BMD T-score &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Men receiving androgen deprivation therapy for prostate cancer &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Women receiving aromatase inhibitor therapy for breast cancer &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Long-term or repeated systemic corticosteroid use (oral or parenteral) that does not meet the conventional criteria for recent prolonged systemic corticosteroid use (i.e., &amp;ge;3 consecutive months) therapy at a dose of prednisone &amp;ge;7.5 mg per day or equivalent) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Recurrent falls &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;High risk&lt;/em&gt;: Consider medication in addition to lifestyle advice and adequate daily intake of calcium and vitamin D. Patients with hip and other fragility fractures are considered to be high risk. Individuals can be considered as candidates for medication after implementing fall prevention strategies and providing lifestyle advice (see Step 3, above). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;OP medications available in Canada include (alphabetically): alendronate, calcitonin, denosumab, estrogens (with or without progesterone), etidronate, raloxifene, risedronate, teriparatide, and zoledronic acid. Data are insufficient to determine if one drug class is superior to another for fracture prevention. Medication adherence (compliance and persistence) is required for fracture reduction, yet rates of adherence to OP treatments are low.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Consider barriers to adherence including mode of administration, dosing regimens, side effects, and cost (see &lt;em&gt;Appendix D - Pharmacological Therapy for Osteoporosis&lt;/em&gt; in the original guideline document). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Combine adequate calcium and vitamin D with all pharmacological treatments (see Step 3: Lifestyle Advice, above). For information regarding PharmaCare coverage of these medications please refer to Appendix D in the original guideline document. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Bisphosphonates&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;These drugs preserve bone by decreasing rate of bone turnover and enhancing bone mineralization. To date, this class of drugs (specifically alendronate, risedronate, and zoledronic acid) has the largest body of randomized controlled trial evidence for osteoporosis. Superiority of one bisphosphonate over another has not been conclusively shown. Most studies have been in post-menopausal women and the optimal duration of therapy is unknown (to date most studies, with fractures as an endpoint, have had an average five years duration).&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Bisphosphonates&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Bisphosphonates&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Points to Consider&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Alendronate (oral) &amp;amp;&lt;br /&gt;&#xD;&#xA;            Risedronate (oral)&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Post-menopausal women: prevents vertebral, non-vertebral, and hip fractures &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Men: Some evidence of decreased risk of vertebral fractures; some evidence of increased hip bone density, but no significant hip fracture reduction &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Glucocorticoid induced osteoporosis (GIO): Some evidence of decreased vertebral fracture risk &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Etidronate (oral)&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Post-menopausal women: prevents vertebral fractures &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;GIO: maintains BMD in GIO although data is limited; Health Canada approved indication is for GIO prevention only (not treatment) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Zoledronic acid (intravenous)&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Post-menopausal women: prevents vertebral, non-vertebral, and hip fractures &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Men: Data is limited; Some evidence of decreased risk of vertebral and non-vertebral fractures (study included those with prior hip fracture and only 24% men) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;GIO: maintains BMD &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cost effectiveness may limit use &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Consider for high-risk patients who are unable to tolerate oral therapy or have poor adherence &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Selective Estrogen Receptor Modulators (SERMs) (Raloxifene)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;SERMs can act as estrogen agonists or antagonists. Raloxifene acts as an estrogen agonist on bone tissue. The estrogenic effects of raloxifene on bone in postmenopausal women decrease bone turnover.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Selective Estrogen Receptor Modulators (SERMs) (Raloxifene)&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Drug&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Points to Consider&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Raloxifene (oral)&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Post-menopausal women: reduces the incidence of vertebral fractures &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;May be considered in post-menopausal women who are unable to tolerate bisphosphonates and have no history of thromboembolic disease &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Caution: Significantly increases the risk of venous thromboembolic disease and stroke &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Receptor Activator of Nuclear Factor-kB (RANK) Ligand Inhibitor&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Denosumab is an injectable monoclonal antibody to the receptor activator of nuclear factor-kB ligand (RANKL). It inhibits bone resorption by osteoclasts by blocking the interaction between RANKL and its receptor RANK on the surface of osteoblasts.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Receptor Activator of Nuclear Factor-kB (RANK) Ligand Inhibitor&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Drug&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Points to Consider&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Denosumab (subcutaneous)&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Post-menopausal women: prevents vertebral, non-vertebral, and hip fractures &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cost and lack of long term safety data may limit use &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Synthetic Parathyroid Hormone&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Teriparatide is an anabolic agent that improves bone quality, quantity, and increases bone strength.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Synthetic Parathyroid Hormone&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Drug&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Points to Consider&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Teriparatide (subcutaneous)&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Post-menopausal women: prevents vertebral and non-vertebral fractures in postmenopausal women with severe OP &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Men: increases BMD; currently no fracture data available &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;GIO: Some evidence of benefit in the treatment of GIO &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cost and need for daily subcutaneous injection may limit use &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Consider for patients at increased risk of fracture or lack of response to other therapies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Maximum lifetime exposure is 24 months &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Bisphosphonates must be discontinued prior to treatment &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Gains in BMD decline once treatment with teriparatide is discontinued; consider anti-resorptive therapy after completing treatment course &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Calcitonin Peptides&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Calcitonin salmon is an inhibitor of bone resorption; available in parenteral and nasal spray formulations. Although calcitonin does not build bone, in women &amp;gt;5 years beyond menopause, it appears to slow bone loss and increase spinal bone density.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Calcitonin Peptides&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Drug&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Points to Consider&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Calcitonin (nasal)&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Post-menopausal women: Reduces incidence of vertebral fractures; however evidence for benefit is limited &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Consider as an alternative when other more effective drugs cannot be used &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Effective in decreasing acute pain associated with vertebral osteoporotic fractures &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Calcitonin injection is currently not approved for the treatment of OP; it is sometimes prescribed for patients who have pain due to acute vertebral fractures (See &lt;em&gt;Appendix D - Pharmacological Therapy for Osteoporosis&lt;/em&gt; in the original guideline document) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Nasal route of administration has the most data for use in OP and is more commonly used due to convenience and tolerability &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Hormone Replacement Therapy (HRT) (estrogen with or without progesterone)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;HRT is primarily indicated for the management of moderate to severe menopausal symptoms in women. A beneficial effect has been seen on BMD and fracture risk due to the significant anti-resorptive activity of estrogen.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Hormone Replacement Therapy (HRT)&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Drug&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Points to Consider&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;HRT (oral or transdermal)&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Post-menopausal women: Shown to prevent vertebral, hip and non-vertebral fractures &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Is not recommended for the sole indication of OP prevention and for long term use for this indication; consider benefits versus risks (See &lt;em&gt;Appendix D - Pharmacological Therapy for Osteoporosis&lt;/em&gt; in the original guideline document) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;May be appropriate for OP prevention when it is already being used for the management of menopausal symptoms &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Step 5: Monitoring&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Clinical Re-assessment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Re-assess patients as clinically indicated to monitor side effects, compliance, height loss, incident fractures, and risk of falls, which may alter patient management.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Follow-up BMD Measurements&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There is insufficient evidence to recommend a testing frequency for patients not taking OP medications. Based on a patient's risk profile, BMD retesting may be indicated in 3-10 years.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For patients on OP medication, repeat BMD examinations are not justified based on current evidence. If a BMD is to be done, any changes would be difficult to detect prior to 3 years. Consider more frequent testing in specific high risk situations (e.g., multiple risk factors, or receiving &amp;ge;7.5 mg prednisone daily or its equivalent for 3 months consecutively who require a baseline examination and repeat scans at 6-month intervals while on treatment).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Women &amp;gt;65 years will usually lose bone. A stable BMD value on treatment may reflect successful treatment and appreciable decreases in fracture risk may accompany minor increases in BMD. Minor increases in BMD may also be due to testing variance. Ideally, any follow-up BMD testing is recommended to be done on the same&amp;nbsp;DXA machine and at the same time of year.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A clinical algorithm on recommendations for evaluation and management of osteoporotic and fragility fracture risk is provided in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is not specifically stated for each recommendation.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Accurate diagnosis and appropriate treatment of osteoporosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Effective prevention of fractures &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Side effects for medication are listed in &lt;em&gt;Appendix D - Pharmacological Therapy for Osteoporosis&lt;/em&gt; in the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Calcium&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A 2010 meta-analysis reported an increase in myocardial infarction in men and women given calcium supplementation (i.e., &amp;ge;500 mg elemental calcium per day) versus placebo. Note: this meta-analysis studied calcium supplementation alone and not in combination with vitamin D and the increased risk was associated with dietary intakes of greater than 800 mg (approximately) elemental calcium per day.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Alendronate&lt;/em&gt; is contraindicated in patients with renal impairment (i.e., creatinine clearance [CrCl] &amp;lt;30 mL/min) or hypocalcemia. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Teriparatide&lt;/em&gt; is contraindicated in patients with severe renal impairment or hypercalcemia and during pregnancy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Raloxifene&lt;/em&gt; is contraindicated in pregnancy, and in patients with a history of venous thromboembolic events (VTE). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Denosumab&lt;/em&gt; is contraindicated in patients with hypocalcemia. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Conjugated estrogen&lt;/em&gt; is contraindicated in patients with a history of thromboembolic events or breast cancer. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Clinical Practice Guidelines (the &quot;Guidelines&quot;) have been developed by the Guidelines and Protocols Advisory Committee on behalf of the Medical Services Commission. The Guidelines are intended to give an understanding of a clinical problem, and outline one or more preferred approaches to the investigation and management of the problem. The Guidelines are not intended as a substitute for the advice or professional judgment of a health care professional, nor are they intended to be the only approach to the management of clinical problems.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Chart Documentation/Checklists/Forms" /><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Mobile Device Resources" /><FieldValue Value="Patient Resources" /><FieldValue Value="Quick Reference Guides/Physician Guides" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Medical Services Commission. Osteoporosis: diagnosis, treatment and fracture prevention. Vancouver (BC): British Columbia Medical Services Commission; 2011 May 1. 15 p.  [41 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2011 May" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Medical Services Commission, British Columbia - State/Local Government Agency [Non-U.S.]" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Medical Services Commission, British Columbia&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guidelines and Protocols Advisory Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.bcguidelines.ca/guideline_osteoporosis.html&quot; title=&quot;BC Ministry of Health Web site&quot;&gt;British Columbia Ministry of Health Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Osteoporosis: diagnosis, treatment and fracture prevention. Summary of guideline. Victoria (BC): British Columbia Medical Services Commission; 2011 May 1. 2 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.bcguidelines.ca/pdf/osteoprosis_summary.pdf&quot; title=&quot;British Columbia Ministry of Health Web site&quot;&gt;British Columbia Ministry of Health Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;In addition, a link to the FRAX Calculator to Assess Absolute Fracture Risk is available in Appendix C in the &lt;a href=&quot;http://www.bcguidelines.ca/guideline_osteoporosis.html&quot; title=&quot;British Columbia Ministry of Health Web site&quot;&gt;original guideline document&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Osteoporosis and fracture prevention. A guide for patients. Victoria (BC): British Columbia Medical Services Commission; 2011 May. 3 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.bcguidelines.ca/pdf/osteoporosis_patient_guide.pdf&quot; title=&quot;British Columbia Ministry of Health Web site&quot;&gt;British Columbia Ministry of Health Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on December 21, 2011.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
